Financial Review: PPJ Enterprise (OTCMKTS:PPJE) vs. Evaxion A/S (NASDAQ:EVAX)

PPJ Enterprise (OTCMKTS:PPJE) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Institutional & Insider Ownership

11.0% of Evaxion A/S shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for PPJ Enterprise and Evaxion A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PPJ Enterprise	0	0	0	0	0.00
Evaxion A/S	1	0	5	0	2.67

Evaxion A/S has a consensus price target of $11.00, indicating a potential upside of 144.99%. Given Evaxion A/S’s stronger consensus rating and higher probable upside, analysts plainly believe Evaxion A/S is more favorable than PPJ Enterprise.

Valuation and Earnings

This table compares PPJ Enterprise and Evaxion A/S”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PPJ Enterprise	$670,000.00	0.00	$10,000.00	N/A	N/A
Evaxion A/S	$7.53 million	4.97	-$7.71 million	($1.32)	-3.40

PPJ Enterprise has higher earnings, but lower revenue than Evaxion A/S.

Profitability

This table compares PPJ Enterprise and Evaxion A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PPJ Enterprise	N/A	N/A	N/A
Evaxion A/S	N/A	-61.43%	-29.14%

Volatility and Risk

PPJ Enterprise has a beta of -0.27, meaning that its stock price is 127% less volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500.

Summary

Evaxion A/S beats PPJ Enterprise on 7 of the 10 factors compared between the two stocks.

About PPJ Enterprise

PPJ Healthcare Enterprises, Inc., through its subsidiaries, provides automated healthcare reimbursement cycle, online health information digital-systems, and practice information management digital-system software to health care providers and general businesses worldwide. The company offers the Automated Biller, a medical billing system that allows physicians to bill their medical insurance claims at the point of service without data entry, coding, or billing personnel. It also provides billing, specialty medical billing, collection, and workers comp lien collection services for health care providers in the areas of pain management, anesthesia and surgery centers practices, and various specialties of medicine. The company was formerly known as PPJ Enterprise and changed its name to PPJ Healthcare Enterprises, Inc. in October 2014. PPJ Healthcare Enterprises, Inc. was founded in 2000 and is headquartered in Reno, Nevada.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.